TXMDNasdaqPharmaceutical PreparationsFiscal year ends December 31

TherapeuticsMD, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$1.86−0.04 (-2.11%)

Close on Oct 19, 2026

Market cap: $21.66M
P/E (TTM): –
Dividend yield: –

TherapeuticsMD, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Cash & Equivalents	7.48	5.06	4.33	49	65	80	161	162	127	132	65	51	54	1.55	0.13	0.42	0.00
Cash & Short-Term Investments	7.48	5.06	4.33	49	65	80	161	162	127	132	65	51	54	1.55	0.13	0.42	0.00
Receivables	–	–	–	–	36	32	24	11	4.33	4.50	3.05	2.15	1.69	0.71	0.03	–	–
Inventory	–	–	–	–	7.62	7.99	12	3.27	1.49	1.08	0.69	1.18	1.04	1.62	0.59	–	–
Prepaid Expenses & Other	3.44	3.64	4.04	6.03	5.86	7.54	11	11	6.60	2.30	2.23	1.54	2.48	–	0	–	–
Other Current Assets	–	–	–	–	–	–	–	–	–	–	–	–	2.48	0.75	0.50	–	–
Total Current Assets	14	12	12	55	119	128	208	187	140	139	71	56	59	4.64	1.24	0.00	–
Property, Plant & Equipment	–	–	–	0.08	0.82	1.94	2.51	0.47	0.44	0.52	0.20	0.06	0.06	0.07	0.03	–	–
Gross Property, Plant & Equipment	–	–	2.52	2.52	2.79	3.68	3.48	1.03	0.81	0.75	0.35	0.19	0.16	0.13	0.06	–	–
Accumulated Depreciation	–	–	-2.52	-2.45	-1.97	-1.74	-0.97	-0.55	-0.37	-0.23	-0.15	-0.12	-0.09	-0.06	-0.03	–	–
Operating Lease Right-of-Use Assets	5.29	6.10	6.87	7.58	8.23	9.57	10	3.80	–	–	–	–	–	–	–	–	–
Intangible Assets	3.76	4.32	6.10	6.94	7.14	41	5.26	4.09	3.10	2.41	1.62	1.23	0.67	0.24	–	–	–
Other Long-Term Assets	0.44	0.13	0.06	0.25	0.25	0.25	55	25	–	–	–	–	–	–	0.08	–	–
Total Assets	38	39	43	90	169	182	266	212	143	142	74	59	62	5.93	1.44	0.47	–
Accounts Payable	0.38	0.26	0.03	2.16	3.37	21	19	23	4.10	7.36	3.13	6.33	2.11	1.64	0.31	0.00	–
Current Portion of Long-Term Debt	–	–	–	–	188	–	–	–	–	–	–	–	–	–	–	–	–
Current Debt	–	–	–	–	188	–	–	–	–	–	–	–	–	–	–	–	–
Current Portion of Leases	0.98	1.63	1.47	1.39	1.36	2.25	1.50	–	–	–	–	–	–	–	–	–	–
Other Current Liabilities	–	–	–	19	13	38	34	18	9.22	7.62	7.54	3.84	3.60	0.83	0.47	–	–
Total Current Liabilities	4.79	5.17	6.85	47	253	59	53	41	13	15	11	11	7.32	3.62	3.15	1.37	–
Long-Term Debt	–	–	–	–	0	238	195	73	–	–	–	–	–	3.59	–	–	–
Long-Term Leases	5.12	5.54	6.53	7.37	8.06	8.68	9.15	–	–	–	–	–	–	–	–	–	–
Operating Lease Liabilities	6.10	7.18	8.01	8.76	9.42	11	11	4.10	–	–	–	–	–	–	–	–	–
Other Long-Term Liabilities	0.87	0.74	0.64	1.11	2.14	–	–	–	–	–	–	–	–	–	–	–	–
Total Liabilities	11	11	14	55	263	306	257	114	13	15	11	11	7.32	7.36	3.15	1.37	–
Total Debt	–	–	–	–	188	238	195	73	–	–	–	–	–	3.59	–	–	–
Preferred Stock	–	–	–	–	0	0	–	–	–	–	–	–	–	–	–	–	–
Common Stock	0.01	0.01	0.01	0.01	0.01	0.30	0.27	0.24	0.22	0.20	0.18	0.16	0.14	0.10	0.08	0.02	–
Additional Paid-In Capital	979	979	979	974	958	755	704	617	516	437	283	183	135	51	15	1.66	–
Retained Earnings	-952	-952	-950	-939	-1,051	-879	-695	-519	-387	-310	-220	-135	-81	-52	-17	-2.59	–
Shareholders' Equity	27	27	29	35	-94	-124	9.20	98	130	127	63	48	55	-1.43	-1.71	-0.91	–
Total Equity	27	27	29	35	-94	-124	9.20	98	130	127	63	48	55	-1.43	-1.71	0.96	0.48
Total Liabilities & Equity	38	39	43	90	169	182	266	212	143	142	74	59	62	5.93	1.44	0.47	–
Shares Outstanding(shares)	12	12	12	9.50	8.60	6.00	5.42	4.81	4.33	3.93	3.56	3.12	2.90	2.00	1.66	1.11	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -120.9%
Net margin: -6.6%
Return on equity, FY2025: -2.1%

Financial strength

Current ratio: 3.22
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 183.7%

Valuation

P/E ratio: –
Price to sales: 6.62
Price to book: 0.80
Dividend yield: –